Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
608 in Active Ankylosing Spondylitis
NCT07261644Phase 3Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 3 trial of 608 in ankylosing spondylitis (AS), sponsored by 3S Guojian Pharmaceutical. Started Nov 2025; status: recruiting.
02
Drugs
608
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07261644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261644.